SecBot SecBot
8-K ·Filed Aug 11, 2026

RARE

Ultragenyx Pharmaceutical Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0001193125-26-343525
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The settlement removes near-term overhang from this specific ANDA filer but establishes a clear generic entry timeline for DOJOLVI. Monitor progress of remaining ANDA litigations and any FTC/DOJ challenge to the settlement. The 2033 generic entry date is distant, so near-term revenue impact is minimal, but the settlement signals that patent protection may not extend beyond that window.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$26.80
T+0 close · Aug 11, 2026 · via day close
Latest settled
−34.79%
T+60 · $17.48
Vs SPY
−34.66%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $26.80entry
  2. T+1 · 3mo ago +0.22%α −0.03% · $26.86
  3. T+5 · 3mo ago −4.89%α −4.48% · $25.49
  4. T+20 · 2mo ago −46.60%α −45.55% · $14.31
  5. T+60 · 13d ago −34.79%α −34.66% · $17.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ultragenyx settled patent litigation with Esjay Pharma over generic DOJOLVI (triheptanoin). Esjay gets a non-exclusive, royalty-free license to market its generic version starting January 1, 2033 (extended to July 1, 2033 if pediatric exclusivity is granted). The settlement removes near-term generic risk but sets a definitive loss of exclusivity date, while litigation against other ANDA filers remains pending. No financial terms were disclosed, and the agreement is subject to FTC/DOJ review.

Key Facts

  • Ultragenyx settled DOJOLVI patent litigation with Esjay Pharma on August 7, 2026.
  • Esjay receives a non-exclusive, royalty-free license to market generic DOJOLVI starting January 1, 2033 (or July 1, 2033 if pediatric exclusivity is granted).
  • Litigation against other ANDA filers for DOJOLVI remains pending in the District of New Jersey.
  • The settlement agreement will be submitted to the FTC and DOJ as required by law.
  • No financial terms of the settlement were disclosed.

Financial Impact

No financial terms disclosed; settlement removes litigation uncertainty but establishes a definitive generic entry date of January 1, 2033 (or July 1, 2033 with pediatric exclusivity).

revenuedilution

Risk Factors

  • Remaining ANDA litigations could result in earlier generic entry if not settled on similar terms.
  • FTC or DOJ could challenge the settlement agreement as anticompetitive.
  • Loss of exclusivity for DOJOLVI in 2033 will materially reduce revenue from the product.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-343525
Document: 0001193125-26-343525-index.html0001193125-26-343525
Document: 0001193125-26-343525.txt0001193125-26-343525

Track record

22 reports on RARE

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
  3. Nov 3, 202613d ago 8-K Mixed 6/10 No price data
  4. Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
  5. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
  6. Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
  7. Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
  8. Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
  9. Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
  10. Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 7h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026